Geoffrey R. Oxnard, MD

Articles by Geoffrey R. Oxnard, MD

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

ByEthan Sokol,Smruthy Sivakumar,Dexter X. Jin,Hanna Tukachinsky,Karthikeyan Murugesan,Dean Pavlick,Jeffrey S. Ross, MD,Garrett M. Frampton,Geoffrey R. Oxnard, MD,Priti S. Hegde

April 18th 2022

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

ByGeoffrey R. Oxnard, MD,Vincent A. Miller, MD

April 30th 2010

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of patients with non–small-cell lung cancer (NSCLC).

Latest Updated Articles

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC
Published: April 30th 2010 | Updated:

Geoffrey R. Oxnard, MD

Articles by Geoffrey R. Oxnard, MD

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

Latest Updated Articles

Trending on CancerNetwork

FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC

FDA Grants Regular Approval to Rucaparib in Metastatic CRPC

Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer

All-Oral Elacestrant Combos Offer “Tremendous” Benefits in Breast Cancer

Pelareorep Exhibits Activity in Second-Line KRAS-Mutated Metastatic CRC